Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Tuan, Meisel, Andreas, Mantegazza, Renato, Annane, Djillali, Katsuno, Masahisa, Aguzzi, Rasha, Enayetallah, Ahmed, Beasley, Kathleen N., Rampal, Nishi, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Summary of Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444731/
https://www.ncbi.nlm.nih.gov/pubmed/37351816
http://dx.doi.org/10.1007/s40120-023-00514-4
Descripción
Sumario:This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00514-4.

Ejemplares similares